Trials / Completed
CompletedNCT00334360
Dexmed/Buspirone Synergism on Shivering
Do Dexmedetomidine and Buspirone Synergistically Reduce the Threshold, Gain, and Maximum Intensity of Shivering?
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- The Cleveland Clinic · Academic / Other
- Sex
- Male
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research is to determine if the combination of buspirone and dexmedetomidine are effective as a treatment to induce therapeutic hypothermia. The design of the study includes four study days done in random order. The days are as follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6 ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted into the other arm for drug administration. Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and lower-body will individually be maintained at the designated skin temperature. Lactated Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen consumption or electromyographic intensity (see below) continues to increase or a total of 5 liters of fluid is given. Heart rate will be measured continuously using an electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of the baseline), the study will stop and the volunteer will be re-warmed immediately.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexmedetomidine | Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia |
| DRUG | buspirone | Buspirone, 60 mg orally, will be given during controlled hypothermia. |
| DRUG | Bus and Dex | the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia |
| DRUG | Control | No drugs given during controlled hypothermia |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-06-07
- Last updated
- 2016-06-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00334360. Inclusion in this directory is not an endorsement.